Smith & Nephew


Q2 20, a trough left behind

30/07/20 -"Smith & Nephew reported big declines in Q2 20 with sales down 29.3% on an underlying basis – driven by broad-based declines – and the H1 20 trading profit margin contracting by 12.9pp (to ..."

Pages
52
Language
English
Published on
30/07/20
You may also be interested by these reports :
11/08/20
A few months after our last teaser in September 2019, EssilorLuxottica/EL (Add, France)  touched a new lifetime high – led by a sales ...

06/08/20
Impacted by the temporary closure of clinics and the deferral of elective procedures, CZM’s Q3 sales were down 30.2% – ophthalmic devices as well as ...

06/08/20
Galenica released a mixed set of H1 20 numbers: sales were up by 5.6%, while adjusted operating profits increased by an unimpressive 3% (vs consensus ...

05/08/20
Sales momentum accelerated in Q2 20, benefiting from robust demand for COVID-19 solutions. Q3 is expected to be strong and, given the improved ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO